References
- Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3. doi:10.1007/978-1-4419-0284-9_1.
- Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011(1357-714X):548151. doi:10.1155/2011/548151.
- Bielack SS, Kempf-Bielack B, Delling Gn. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790. doi:10.1200/JCO.2002.20.3.776.
- Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–655. doi:10.1016/j.cell.2009.01.035.
- Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–524. doi:10.1101/gad.1399806.
- Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653–4662. doi:10.1242/dev.02073.
- Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7. doi:10.1016/j.cell.2005.06.036.
- Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 2009;60:167–179. doi:10.1146/annurev.med.59.053006.104707.
- Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol. Cancer Ther. 2008;7:3655–3660. doi:10.1158/1535-7163.MCT-08-0586.
- Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumor Biol. 2013;34:2093–2098. doi:10.1007/s13277-013-0940-7.
- Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu Y, Shi J, Sun X, Liu Y, Ding Y, et al. MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial–mesenchymal transition in colorectal cancer. Cancer Lett. 2016;373:203–213. doi:10.1016/j.canlet.2016.01.037.
- Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q, Yang W, Zheng X, Tu K, Liu Q. miR-187-3p inhibits the metastasis and epithelial–mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 2016;381:380–390. doi:10.1016/j.canlet.2016.08.011.
- Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y, Fan S, Liu Y. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem Biophys Res Commun. 2013;438:439–444. doi:10.1016/j.bbrc.2013.07.095.
- Casanova-Salas I, Masiá E, Armiñán A, Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ. MiR-187 targets the androgen-regulated gene ALDH1A3 in prostate cancer. PLoS One. 2015;10:e0125576. doi:10.1371/journal.pone.0125576.
- Wijnhoven B, Hussey D, Watson D, Tsykin A, Smith C, Michael M. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010;97:853–861. doi:10.1002/bjs.7000.
- Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG, et al. miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res. 2012;18:6702–6713. doi:10.1158/1078-0432.CCR-12-1420.
- Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene. 2012;31:764–775. doi:10.1038/onc.2011.269.
- Lulla RR, Costa FF, Bischof JM. Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma. 2011:732690. doi:10.1155/2011/732690.
- Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014;31:1–9. doi:10.1007/s12032-014-0970-z.
- Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci U S A. 2006;103:14825–14830. doi:10.1073/pnas.0606747103.
- Cao C, Yang F, Wang P, Yang Q, Sun X. Clinicopathologic significance of S100A4 expression in osteosarcoma. Eur Rev Med Pharmacol Sci. 2014;18:833–839.
- Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003;20:701–711. doi:10.1023/B:CLIN.0000006819.21361.03.